Vaccines (Mar 2022)

Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers

  • Cristina Costa,
  • Enrica Migliore,
  • Claudia Galassi,
  • Gitana Scozzari,
  • Giovannino Ciccone,
  • Maurizio Coggiola,
  • Enrico Pira,
  • Antonio Scarmozzino,
  • Giovanni La Valle,
  • Paola Cassoni,
  • Rossana Cavallo,
  • on behalf of the Collaborative Group

DOI
https://doi.org/10.3390/vaccines10030474
Journal volume & issue
Vol. 10, no. 3
p. 474

Abstract

Read online

We aimed at evaluating quantitative IgG response to BNT162b2 COVID-19 vaccine among health care workers (HCW), and exploring the role of demographic, clinical, and occupational factors as predictors of IgG levels. On May 2021, among 6687 HCW at the largest tertiary care University-Hospital of Northwestern Italy, at a median of 15 weeks (Interquartile range-IQR 13.6–16.0) after second-dose, serological response was present in 99.8%. Seropositivity was >97% in all the subgroups, except those self-reporting immunodeficiency (94.9%). Overall, the median serological IgG value was 990 BAU/mL (IQR 551–1870), with most of subjects with previous SARS-CoV-2 infection or with shorter time lapse (2–8 weeks) between vaccination and serology with values in the highest quintile (>2080). At multivariable analysis, significant predictors of lower values were increasing age, male, current smoking, immunodeficiency, recent occupational contacts, and increasing time lapse from vaccination; conversely, previous infection and recent household contacts were significantly associated with higher IgG levels. Subjects with previous infection kept a very high level (around 2000 BAU/mL) up to 120 days. These results, besides supporting a high serological response up to 4–5 months, suggest predictive factors of faster decay of IgG levels that could be useful in tailoring vaccination strategies.

Keywords